10X Genomics Inc (TXG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 10X Genomics Inc (TXG) has a cash flow conversion efficiency ratio of 0.055x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($43.21 Million) by net assets ($786.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TXG defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
10X Genomics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how 10X Genomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
10X Genomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 10X Genomics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Lihexing Co. Ltd.
SHE:301013
|
-0.034x |
|
Saigon Beer Alcohol Beverage Corp
VN:SAB
|
0.101x |
|
Jiangsu Yunyi Electric
SHE:300304
|
0.032x |
|
Shaanxi Ligeance Mineral Resources Co Ltd
SHE:000697
|
0.002x |
|
Yantai Tayho Advanced Materials Co Ltd
SHE:002254
|
0.045x |
|
Shanghai Huafon Aluminium Corp
SHG:601702
|
-0.011x |
|
Xinxing Ductile Iron Pipes Co Ltd
SHE:000778
|
-0.010x |
|
Dongyue Group Limited
F:4D3
|
0.018x |
Annual Cash Flow Conversion Efficiency for 10X Genomics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of 10X Genomics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see TXG market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $710.13 Million | $6.66 Million | 0.009x | +145.76% |
| 2023-12-31 | $741.04 Million | $-15.20 Million | -0.021x | +50.83% |
| 2022-12-31 | $805.74 Million | $-33.61 Million | -0.042x | -59.54% |
| 2021-12-31 | $817.57 Million | $-21.37 Million | -0.026x | +91.13% |
| 2020-12-31 | $739.07 Million | $-217.90 Million | -0.295x | -457.67% |
| 2019-12-31 | $420.08 Million | $34.63 Million | 0.082x | -76.27% |
| 2018-12-31 | $-219.99 Million | $-76.41 Million | 0.347x | +265.25% |
| 2017-12-31 | $-112.51 Million | $-10.70 Million | 0.095x | -- |
About 10X Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and … Read more